BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20260808T052422EDT-7637bcUF8n@132.216.98.100
DTSTAMP:20260808T092422Z
DESCRIPTION:Laurent Azoulay\, PhD\n\nAssociate-Professor – Department of On
 cology\n	Associate-Member – Department of EBOH\n	Faculty of Medicine\, McGil
 l University\n	Investigator\, Centre for Clinical Epidemiology\, LDI-JGH\n
 \nPioglitazone and the risk of bladder cancer: An ongoing saga\n\nALL ARE 
 WELCOME\n\nAbstract:\n\nPioglitazone is an antidiabetic drug that has been
  shown to improve glycemic levels in patients with type 2 diabetes. Howeve
 r\, its safety is controversial\, with earlier studies associating its use
  with an increased risk of bladder cancer. While the findings of these stu
 dies led to a black-box warning on the drug’s label\, recent studies with 
 longer follow-up have failed to observe an association\; but these had imp
 ortant methodological shortcomings. In this seminar\, I will present the f
 indings of a large population-based study that used a robust pharmacoepide
 miologic approach to address different sources of bias. This study fits wi
 thin a broader research program in cancer pharmacoepidemiology.\n\nObjecti
 ves:\n\nTo review the role of pharmacotherapies in the management of type 
 2 diabetes\n	To review the controversies associating pioglitazone with blad
 der cancer\n	To acquire new knowledge of the possible association between p
 ioglitazone and bladder cancer\nBio:\n\nDr. Laurent Azoulay is an Associat
 e Professor in the Department of Oncology\, 91Ë¿¹ÏÊÓƵ. He received
  his PhD in 2007 from the Université de Montréal\, and then joined 91Ë¿¹ÏÊÓƵ 
 University in 2009. His research interests are primarily in cancer pharmac
 oepidemiology. He has conducted numerous studies assessing the association
  between commonly prescribed drugs and cancer incidence\, as well as evalu
 ating the short- and long-term safety of cancer treatments. His research p
 rogram is funded by a CIHR Foundation Scheme grant.\n\nhttp://www.medicine
 .mcgill.ca/oncology/fac/facandstaff_show.asp?Oncology...\n
DTSTART:20160222T210000Z
DTEND:20160222T220000Z
LOCATION:Room 521\, McIntyre Medical Building\, CA\, QC\, Montreal\, H3G 1Y
 6\, 3655 promenade Sir William Osler
SUMMARY:Special Epidemiology Seminar: 'Pioglitazone and the risk of bladder
  cancer: An ongoing saga'
URL:/channels/event/special-seminar-258504
END:VEVENT
END:VCALENDAR